Management of One Patient With Oligoprogressive Thyroid Cancer During Treatment With Lenvatinib

Future Oncology - United Kingdom
doi 10.2217/fon-2019-0110
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Treatment With Lenvatinib to Anaplastic Thyroid Cancer :

JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
2018English

Administration of Lenvatinib to Patients With Anaplastic Thyroid Cancer

JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
2018English

Optimal Use of Lenvatinib in the Treatment of Advanced Thyroid Cancer

Cancers of the Head & Neck
2017English

Lenvatinib as a Novel Treatment for Anaplastic Thyroid Cancer: A Retrospective Study

Oncology Letters
Cancer ResearchOncology
2018English

Carnitine Insufficiency Is Associated With Fatigue During Lenvatinib Treatment in Patients With Hepatocellular Carcinoma

PLoS ONE
Multidisciplinary
2020English

Sequential Analysis of Neutrophil-To-Lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Lenvatinib vs. Palliative Therapy for Stage IVC Anaplastic Thyroid Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2019English

A Systematic Review of Lenvatinib and Sorafenib for Treating Progressive, Locally Advanced or Metastatic, Differentiated Thyroid Cancer After Treatment With Radioactive Iodine

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Cohort Study Exploring the Effect of Lenvatinib on Differentiated Thyroid Cancer

Endocrine Journal
EndocrinologyMetabolismDiabetes
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy